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The insulin/insulin growth factor (IGF) signaling (IIS)
pathway is a key regulator of aging of worms, flies,
mice, and likely humans. Delayed aging by IIS reduc-
tion protects the nematode C. elegans from toxicity
associated with the aggregation of the Alzheimer’s
disease-linked human peptide, Ab. We reduced IGF
signaling in Alzheimer’s model mice and discovered
that these animals are protected from Alzheimer’s-
like disease symptoms, including reduced behav-
ioral impairment, neuroinflammation, and neuronal
loss. This protection is correlated with the hyperag-
gregation of Ab leading to tightly packed, ordered
plaques, suggesting that one aspect of the protec-
tion conferred by reduced IGF signaling is the
sequestration of soluble Ab oligomers into dense
aggregates of lower toxicity. These findings indicate
that the IGF signaling-regulated mechanism that
protects from Ab toxicity is conserved from worms
to mammals and point to the modulation of this
signaling pathway as a promising strategy for the
development of Alzheimer’s disease therapy.
INTRODUCTION
Most cases of Alzheimer’s disease (AD) exhibit sporadic onset
during the seventh decade of life or later, whereas the fewer
mutation-linked, familial cases typically manifest during the fifth
decade. These temporal features, common to numerous neuro-
degenerative diseases, define aging as the major risk factor for
the development of these maladies (Amaducci and Tesco,
1994). The insulin/insulin-like growth factor (IGF) signaling (IIS)
pathway regulates stress resistance, aging and is a life span
determinant. IIS reduction results in stress-resistant, long-livedworms (Kenyon et al., 1993), flies (Tatar et al., 2001), and mice
(Bluher et al., 2003; Holzenberger et al., 2003) and correlates
with increased longevity of humans (Flachsbart et al., 2009;
Suh et al., 2008; Willcox et al., 2008). Delayed aging, by IIS
reduction, protects worms from proteotoxicity associated with
the aggregation of the Huntington’s disease-associated polyQ
peptide (Morley et al., 2002) and the AD-linked human Ab
peptide (Cohen et al., 2006). However, little is known about
whether this protection from proteotoxicity is conserved from
worms to mammals, and what protective mechanisms may be
operating.
Ab originates from the endoproteolysis of the amyloid
precursor protein (APP) (Glenner and Wong, 1984; Selkoe,
2004). The serine protease BACE (beta amyloid cleaving enzyme)
cleaves APP (Farzan et al., 2000), followed by an intramembrane
cleavage of the resulting fragment by presenilin1 (PS1), an active
component of the g-secretase proteolytic complex (Wolfe et al.,
1999). These events release the Ab family of aggregation-prone
peptides, including Ab1-40 and the highly amyloidogenic Ab1-42.
Although compelling data indicate that Ab aggregation triggers
AD, the mechanism leading to the development of the disease
is unclear (Selkoe, 2004). Recent studies suggest that it is not
fibrils, but small Ab oligomers lead to toxicity in AD model organ-
isms (Cohen et al., 2006; Lesne et al., 2006) and to AD in humans
(Haass and Selkoe, 2007; Shankar et al., 2008).
In the C. elegansAbmodel (Abworms [Link, 1995]), the protec-
tion from human Ab1-42 proteotoxicity conferred by IIS reduction
is dependent upon two transcription factors, heat shock factor 1
(HSF-1), which regulates Ab disaggregation, and DAF-16 (ortho-
log to FOXO in mammals), which facilitates the formation of
larger, less toxic Ab aggregates. Accordingly, Ab worms pro-
tected from Ab toxicity by reduced IIS accumulate more large
Ab aggregates and have fewer oligomers than did their unpro-
tected counterparts with normal IIS (Cohen et al., 2006).
Although reduced IGF signaling extends the life span of mice
(Holzenberger et al., 2003), IGF-1 infusion protects from Ab
toxicity (Carro et al., 2002, 2006), raising the query of whetherCell 139, 1157–1169, December 11, 2009 ª2009 Elsevier Inc. 1157
IGF signaling reduction or activation protects from Ab toxicity. To
address this question, we created an AD mouse model with
reduced IGF signaling by crossing a well-established AD
transgenic mouse model (Jankowsky et al., 2001) with long-lived
mice harboring only one Igf1r gene copy (Igf1r+/ mice) (Holzen-
berger et al., 2003).
RESULTS
Creation of Mice with AD Transgenes in the Context
of Reduced IGF-1R Signaling
Igf1r is the mammalian ortholog of the sole worm insulin/IGF
receptor daf-2 (Kimura et al., 1997). Igf1r+/mice exhibit reduced
IGF-1 signaling, are long-lived, oxidative stress resistant, and
have reduced body size (Holzenberger et al., 2003). The AD
mouse model expresses two AD-linked mutated transgenes,
APPswe (a humanized mouse APP that contains the human Ab
peptide sequence) and human presenilin-1 DE9, both driven by
the mouse prion protein promoter (hereafter referred to as AD
mice) (Jankowsky et al., 2001). The expression of these trans-
genes results in the production of human Ab amyloid, plaque
formation in the brain, and slow, progressive AD-like symptoms
(Jankowsky et al., 2004). The AD-like mice also exhibit age-onset
behavioral impairments, analogous to other AD murine models
(Reiserer et al., 2007). The AD model is less aggressive than
other AD models, exhibiting appearance of Ab plaques in the
brain at 6-7 months of age (Jankowsky et al., 2004). The slow
onset of AD-like symptoms allows for the perturbation of IIS to
examine its role in the age onset requirements of the AD-like
syndrome.
To equalize the genetic background of our mice, we first back-
crossed both the AD and Igf1r+/ mouse strains with wild-type
129 females for three generations, followed by four intercrosses
between the AD and Igf1r+/ mice. Crossing Igf1r+/ with the AD
mice generated offspring of four genotypes (Figure 1A): The orig-
inal parental genotypes, (1) heterozygous Igf1r+/ (Igfr+/) and (2)
AD mice, which served as internal controls (AD). (3) Congenic
siblings that age naturally due to two Igf1r gene copies but
carrying neither of the AD transgenes. These animals served as
negative internal controls for asymptomatic AD-like disease
and natural IGF-1 signaling (WT). Finally, (4) mice harboring
both AD transgenes and only one Igf1r gene copy served as
the experimental group of focus (AD;Igf1r+/).
Quantitative polymerase chain reaction (PCR) analysis
revealed that the expression levels of the APPswe transgene
were nearly identical in brains of AD and AD;Igf1r+/ mice
(Figures S1A–S1E available online), indicating that IGF signaling
reduction does not effect the expression of the prion protein
promoter-driven transgenes. The levels of monomeric Ab and
of the C-terminal APP fragment (APP CTF) were also very similar
in AD and AD;Igf1r+/ mice (Figures S1F and S1G). Similarly,
reduced IGF signaling did not affect the endogenous a and b sec-
retases (ADAM17 and BACE, respectively) in mouse brains of all
genotypes (Figure S1H). Together these results indicate that IGF
signaling reduction affected neither the transgene expression
nor the levels of the endogenous APP processing enzymes or
their activity. As expected, both Igf1r+/ and AD;Igf1r+/mice
were smaller compared with their littermates carrying two1158 Cell 139, 1157–1169, December 11, 2009 ª2009 Elsevier Inc.Igf1r copies, indicating reduced IGF-1R signaling (Figure S2A)
(Holzenberger et al., 2003).
Reduced IGF-1R Signaling Reduces the Behavioral
Deficits of AD Mice
Age-onset memory deficiency and impairment of orientation and
locomotion are associated with Ab production in numerous AD
murine models (Jensen et al., 2005; King and Arendash, 2002;
Westerman et al., 2002). We evaluated whether reduced IGF-1
signaling protects mice from Ab-associated behavioral impair-
ments using several behavioral assays. As an initial analysis, we
used eight animals per genotype and followed their performance
in the Morris water maze test at 3, 6, 9, and 12 months of age, and
found the greatest differences among AD, AD;Igf1r+/ animals
and their littermate controls at the 9 and 12 month time points
(Figures S2B and S2C). At 16 months we observed mortality in
the AD group that was not present in the AD;Igf1R+/ mice
(data not shown). Thus, we refined our behavioral analysis to
the 11-15 month of age using a larger cohort of animals.
We measured the learning ability of mice using a Morris water
maze with a cued (visible) platform for four consecutive days. As
previously reported for other AD model mice (Blanchard et al.,
2008; Westerman et al., 2002), the AD mice did not exhibit a
learning deficiency compared to their age-matched WT, Igf1r+/,
and AD;Igf1r+/ counterparts (Figure 1B, p > 0.05). In order to
test orientation aptitude, we removed the cue from the platform
and recorded the latency time required for mice to locate the
submerged platform for four consecutive days. At days 2, 3,
and 4 of the experiment, AD mice required a significantly (p <
0.05) longer time to find the hidden platform compared to their
WT, Igf1r+/, and AD;Igf1r+/ counterparts (Figure 1C). This indi-
cates that, like other mouse AD models (Jensen et al., 2005; King
and Arendash, 2002; Westerman et al., 2002), orientation capa-
bilities of AD animals are impaired (swim velocities were nearly
identical for all genotypes; Figure S2D). Lastly, we tested
memory skills by removing the platform from the water maze
and recording the number of the crosses of the previous platform
location (probe trial). AD mice crossed the platform’s previous
location significantly (p < 0.05) fewer times than their WT,
Igf1r+/, and most importantly AD;Igf1r+/ counterparts, indi-
cating impaired memory. The observation that AD;Igf1r+/
animals crossed the previous platform location at similar
frequencies compared to WT and Igf1r+/ animals suggests
partial memory restoration (Figure 1D).
Next, we tested the effect of reduced IGF-1 signaling on the
motor skills of AD model mice using a Rota-Rod assay. Much
like the orientation and memory tests, AD mice performed signif-
icantly less well than their age-matched WT, Igf1r+/, and
AD;Igf1r+/ counterparts in this assay (Figure 1E, p < 0.05).
Collectively, the behavioral data revealed that AD mice have
impaired orientation and memory performance as well as loco-
motion impairment that can be delayed by reduced IGF-1
signaling.
Reduced IGF-1R Signaling Reduces Inflammation
and Neuronal Loss in AD Mice
We asked whether the appearance of biological markers associ-
ated with AD-like disease in mice was also delayed by reduced
CB
ED
T
i
m
e
 
o
f
 
l
a
t
e
n
c
y
 
(
s
)
Cued platform
T
i
m
e
 
o
f
 
l
a
t
e
n
c
y
 
(
s
)
Submerged platform
T
i
m
e
 
o
f
 
l
a
t
e
n
c
y
 
(
s
)
RotaRod
Probe trial
AD
AD;Igf1r+/-
Igf1r+/-
WT
AD
AD;Igf1r+/-
Igf1r+/-
WT
W
T
Ig
f1
r+
/-
A
D
A
D
;I
g
f1
r+
/-
W
T
Ig
f1
r+
/-
A
D
A
D
;I
g
f1
r+
/-
P
l
a
t
f
o
r
m
 
f
r
e
q
u
e
n
c
y
 
(
c
r
o
s
s
e
s
)
X
Alzheimer’s (AD) mouse 
model (APPswe / 
Presenilin1ΔE9)
♀ ♂
Long-lived, reduced 
IGF signaling mouse 
(Igf1R+/-)
WT
Wild-type:
No AD transgenes
Natural life span
Igf1r+/-
No AD 
transgenes
Long-lived
AD
AD transgenes
Natural IGF 
signaling
AD;Igf1r+/-
AD transgenes
Altered IGF 
signaling
APPswe hPS1 ΔE9 Igf1r
WT -/- -/- +/+
Igf1r+/- -/- -/- +/-
AD +/- +/- +/+
AD;Igf1r+/- +/- +/- +/-
A
Transgene
Genotype
Genotype table
Figure 1. Reduction of IGF Signaling Protects Mice from Ab-Associated Behavioral Impairments
(A) Long-lived mice carrying one Igf1r copy were crossed with transgenic Alzheimer’s disease (AD) model mice harboring two AD-linked mutated genes, APPswe
(containing the human Ab sequence) and PS1DE9 to obtain offspring of four genotypes: (1) wild-type, harboring two Igf1r copies and no AD-linked transgenes
(WT), (2) long-lived mice with one Igf1r copy and no AD-linked transgenes (Igf1r+/), (3) AD model mice with two Igf1r copies and both AD-linked transgenes (AD),
and (4) mice that harbor one Igf1r copy and both AD-linked transgenes (AD;Igf1r+/).
(B) Latency time for reaching the cued platform significantly decreased through the acquisition sessions (p = 0, F = 35.49, df = 3) in mice of all genotypes (p > 0.05,
F = 1.84, df = 3, n = 8, 15, 16, 18 for AD, AD;Igf1r+/, WT, and Igf1r+/, respectively), suggesting no impairment of learning.
(C) Significant differences were observed amongADmice and their counterparts of the other genotypes in the submerged platform test (p = 5E-4, two-way analysis
of variance [ANOVA], F = 7.71, df = 3,) and across the acquisition days (p = 0.032, F = 2.97, df = 3, n = 8, 15, 16, 18 forAD,AD;Igf1r+/, WT, and Igf1r+/, respectively).
AD mice searched for a longer period of time (p < 0.05. Fisher LSD) for the submerged platform. No difference was observed among the three other genotypes.
(D) AD;Igf1r+/ animals crossed the previous platform location significantly (p = 0.024, Kruskal-Wallis, c2 = 9.38, df = 3) more times than their AD counterparts.
(E) Mice older than the age of plaque formation of all genotypes were tested in a Rota Rod task. Animals of the different genotypes significantly differed in their
performance (p < 0.01, one-way ANOVA, df = 3, F = 4.25; n = 31, 32, 29, and 28 individuals for AD, AD;Igfr+/, Igf1r+/, and wild-type, respectively). AD mice
performed worst among the four genotypes whereas AD;Igfr+/ mice where partially rescued because they performed significantly better than AD animals (p <
0.05, Tuckey LSD). No statistical difference appeared between AD;Igfr+/ animals and the two control genotypes. In all behavioral tests, 11- to 15-month-old
mice were tested and age-match controlled. Error bars represent mean and standard error of the mean (± SEM).Cell 139, 1157–1169, December 11, 2009 ª2009 Elsevier Inc. 1159
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Figure 2. Reduced IGF Signaling Reduces Ab-Associated Neuroinflamation
(A–H) Immunohistochemistry using GFAP antibody indicated reduced astrocytosis in brain sections of 12- to 13-month-old AD;Igf1r+/ mice (D and H) compared
with age-matched AD mice (C and G).
(I) Image analysis confirmed the significance of the GFAP signal difference (six mice per genotype and 3 sections per animal were analyzed, p < 0.05; error bars
represent mean ± SEM).IGF signaling. First we tested whether reactive astrocytosis,
indicative of neuroinflammation, associated with AD in humans
(Mancardi et al., 1983), and with Ab aggregation in brains of
AD model mice (Wirths et al., 2008), was reduced in AD;Igf1r+/
animals. Utilizing glial fibrillary acidic protein (GFAP) antibodies,
which recognize activated astrocytes (Mancardi et al., 1983),
we found notably less activated astrocytes in the brains of
AD;Igf1r+/ mice compared with age-matched AD mice (Fig-
ure 2). This reduction was apparent both in the cortex and hippo-
campus (Figure 2I), indicating that neuroinflammation is reduced
in AD;Igf1r+/ mice compared with age-matched AD mice. Inter-
estingly, whereas the GFAP signal observed in cortices of AD
mice was largely diffuse, cortical GFAP staining of AD;Igf1r+/
mice appeared to be focal (compare Figures 2C and 2D), sug-
gesting that neuroinflammation within AD;Igf1r+/ brains is
confined to smaller areas than in the brains of AD animals.
Neuronal loss is another hallmark of AD in humans (Scheff
et al., 1990) and AD model mice (Masliah and Rockenstein,
2000). We used direct stereological visualization and NeuN
immunoreactivity, a marker of neuronal density that declines in
AD mice, and found higher NeuN immunoreactivity in the
cortices of 12- to 13-month-old AD;Igf1r+/ mice compared to
their age-matched AD counterparts (Figure 3). This indicates
that reduced IGF signaling protects from neuronal loss. Similar
neuronal losses were observed in young (4–5 months of age)
and in old (16–17 months) AD but not in AD;Igf1r+/ mice when
compared to age-matched control genotypes (Figure S3).
Reduced synaptic density is an additional hallmark and prob-
ably causative of AD (Hamos et al., 1989). Thus, we used the
synaptic marker synaptophysin to compare synaptic densities
in frontal and hippocampal brain regions of 12- to 13-month-
old mice of all genotypes (Hamos et al., 1989) and found signif-
icantly lower synaptic densities in both brain regions (Figures 3J
and 3K, respectively) of AD animals compared with their
AD;Igf1r+/ counterparts. These observations confirm that IGF1160 Cell 139, 1157–1169, December 11, 2009 ª2009 Elsevier Inc.signaling reduction protects mice form Ab-associated neuronal
loss.
Reduced IGF Signaling Promotes the Formation
of Densely Packed Aggregates
To explore the mechanism underlying the protection toward
behavioral deficiencies conferred by reduced IGF signaling, as
well as the protection from inflammation and neuronal loss in
mice ectopically expressing mutated AD-linked transgenes, we
investigated the nature of Ab assemblies in brains of AD and
AD;Igf1r+/ mice. Immunohistochemistry (IHC) and Ab anti-
bodies (clone 6E10) were used to visualize Ab plaques in brain
sections of AD and AD;Igf1r+/ mice (Figure S4). Consistent
with previous results (Jankowsky et al., 2004), Ab plaques could
not be detected in brains of young mice (4-5 months old). A few
plaques were observed in the brains of 8- to 9-month-old
animals, whereas the number of plaques increased in the brains
of 12- to 13-month-old AD and AD;Igf1r+/ mice. No background
staining was observed in brains of WT or Igf1r+/ mice at any age
examined (Figure S4). Thus, reduced IGF signaling has no
apparent effect on the onset of plaque formation. Next we
used the fluorescent dye Thioflavin-S to visualize amyloid within
AD and of AD;Igf1r+/ brains and found nearly identical amyloid
load in cortex and hippocampus regions of both genotypes
(Figure 4A, panel IX). (Colocalization of Thioflavin-S labeling
with the signal of specific Ab antibody [clone 82E1] confirmed
the plaque specificity of Thioflavin-S; Figure S5A). Therefore,
the kinetics of Ab plaque appearance as well as the amyloid
load did not appear to differ between AD and AD;Igf1r+/
animals.
Closer inspection of the Ab plaques analyzed by IHC revealed
that plaques observed in the cortices of AD;Igf1r+/ animals are
smaller and more condensed than those detected in the cortices
of their age-matchedAD counterparts (Figure S4, 12–13 months,
insets). To compare the plaque compaction in the mouse brains,
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Figure 3. Reduced IGF Signaling Protects from Ab-Associated Neuronal and Synaptic Loss
(A–H) Immunohistochemistry using NeuN antibody indicated that neural densities in the brains of 12- to 13-month-old AD;Igf1r+/ (D and H), WT (A and E), and
Igf1r+/ (B and F) mice were comparable, while remarkable neuronal loss was observed in brains of age-matched AD animals (C and G).
(I) Image analysis of the NeuN signals indicated that neural density in both cortices and hippocampuses ofAD animals was significantly lower compared with their
age-matched WT counterparts (cortex: p < 0.001, one-way ANOVA, F = 16.03; hippocampus: p < 0.05, Kruskal-Wallis c2 = 9.36, df = 3). No significant difference
was observed among brains of AD;Igf1r+/ and Igf1r+/ mice (six mice per genotype and three sections per animal were analyzed).
(J and K) Immunohistochemistry using synaptophysin antibody revealed that AD;Igf1r+/mice exhibit significantly higher synaptic densities than their
age-matched AD counterparts in both frontal (J) and hippocampal (K) brain regions (AD n = 7, AD;Igf1r+/ n = 5). Error bars represent mean ± SEM.we used the highly specific Ab antibody (clone 82E1 that recog-
nizes processed Ab) and measured the Ab immunoreactive
optical density (signal per area) in the different brains. Signifi-
cantly higher Ab immunoreactive optical densities were detected
in brains of AD;Igf1r+/ mice than in AD brains (Figure 4B, panel
IX), suggesting higher compaction of the Ab amyloid plaques
in AD;Igf1r+/ animals.
We also compared the protease sensitivity of plaques of AD
and AD;Igf1r+/ animals by treating brain sections of 12- to 13-
month-old mice with 10 mg/ml proteinase K prior to their labeling
with Ab antibody. A diffuse staining of Ab plaques seen in AD
brain slices compared to theAD;Igf1r+/ brain slices (Figure S5B)
suggested that plaques of AD;Igf1r+/ animals are more
protease resistant than those of AD mice.
To further analyze the amyloid plaque density, we used post-
embedding immunoelectron microscopy, Ab antibodies, and
gold-labeled protein A. Ab fibrils in the cortex of AD;Igf1r+/
mice appeared to be more densely compacted than those of
their AD counterparts (Figures 5A and S6A). (The lack of immu-noreactivity in the brain sections of WT and Igf1r+/
mice confirmed the specificity of the antibody; Figure S6B).
To quantify and compare the density of the amyloid plaques of
AD and AD;Igf1r+/ mouse brains, we developed an electron
microscopy (EM) image-processing algorithm that identifies
the gold particles conjugated to the Ab antibodies (Figures
S6C–S6F), sets a region of interest (ROI) around each particle,
and determines the median signal density within the ROI after
excluding the gold particle (Figures S6G–S6I). ROIs that contain
dense structures will have a lower score value due to less bright
pixels and more dark pixels (i.e., lower gray-scale value).
Cortices of six 12- to 13-month-old AD mice and five AD;
Igf1r+/ mice were visualized by EM and 135 images (34,087
ROIs) of AD and 101 images (26,066 ROIs) of AD;Igf1r+/ were
automatically segmented and analyzed in an unbiased manner.
The distributions of ROI median signal intensities indicate that
plaques of AD;Igf1r+/ mice were significantly (p < 0.038) denser
than those of age-matched AD counterparts (Figure 5B). The
possibility that antibody accessibility to plaques of AD andCell 139, 1157–1169, December 11, 2009 ª2009 Elsevier Inc. 1161
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Figure 4. Reduced IGF Signaling Facilitates Ab Hyperaggregation
(A) Thioflavin-S amyloid labeling showed similar Ab plaque burden in brains of AD (panels III and VII) and AD;Igf1r+/ animals (panels IV and VIII). Image analysis
indicated that the Thioflavin-S signals are similar in brains of AD and AD;Igf1r+/ mice, but significantly different from WT and Igf1r+/ mice (panel IX). Six 12- to
13-month-old animals per genotype were analyzed.
(B) Ab plaque signal density was measured using Ab-specific antibody (82E1). The signal per area ratio in brains of AD;Igf1r+/ animals (panels IV and VIII) was
significantly higher (panel IX, p < 0.05) compared with brains of age-matched AD animals (panels III and VII), indicating higher plaque compaction in brains of
AD;Igf1r+/ mice (six mice per genotype and three sections per animal were analyzed; DG, dentate gyrus; NC, neocortex). Error bars represent mean ± SEM.AD;Igf1r+/ brains differs was assessed by a second algorithm
designed to measure the distance between each gold particle
and its closest neighboring particle. This algorithm is based on
the assumption that lower accessibility would result in sparse
distribution and longer distances among the gold particles. Auto-
matic processing of all plaque images of AD and AD;Igf1r+/
showed no difference in distances (Figure S6J, p > 0.54), indi-
cating similar antibody accessibilities.
The results obtained using light and electron microscopy
suggest that reduced IGF signaling mediates the assembly of
Ab into more condensed amyloid plaques of lower toxicity. We
used an in vitro kinetic aggregation assay (Cohen et al., 2006)
to assess the relative total amounts of Ab amyloid in equal
volumes of brains of AD and AD;Igf1r+/ mice. When proteinase
K-treated and sonicated (fragments fibrils into a uniform size)
brain homogenate is added to an Ab1-40 aggregation reaction,
the reduction in the time that it takes the aggregation reaction
to reach 50% completion is proportional to the amount of Ab
amyloid fibrils in the tissue (Cohen et al., 2006) (D.D. and J.K.,1162 Cell 139, 1157–1169, December 11, 2009 ª2009 Elsevier Inc.unpublished data). The amyloid load was assessed in 4- to
5-month-old and of 12- to 13-month-old AD and AD;Igf1r+/
mouse brain homogenates (nine animals per genotype). While
no significant difference in aggregate load could be detected
among brain homogenates of young animals (4-5 months old,
Figure S6K), brain extracts of 12- to 13-month-old AD;Igf1r+/
mice exhibit a higher aggregate load reflected by a shorter t50,
(suggesting accelerated aggregation of Ab1-40) relative to age-
matched AD animals (Figure 5C; p = 0.035). These data demon-
strate that there is more amyloids in an equal volume of 12- to
13-month-old AD;Igf1r+/ brain relative to AD brain. These
results are consistent with the light and electron microscopy
data indicating that protected AD;Igf1r+/ animals have more
densely packed Ab aggregates than AD animals.
Reduced IGF-1 Signaling Increases High-MW
Aggregates and Reduces SDS-Soluble Aggregates
The hyperaggregation of Ab by reduced IGF-1 signaling predicts
lower residual amounts of nonaggregated Ab and/or oligomeric
AD AD;Igf1r+/-
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Figure 5. Electron Microscopy and In Vitro Kinetic Aggregation Assays Reveal Densely Packed Ab Aggregates in the Brains of AD;Igf1r+/
Mice
(A) Electron micrographs of immunogold-labeled Ab amyloids in the cortex of AD and AD;Igf1r+/ mouse brains at different ages. Gold-labeled amyloid and
fibrillar Ab structures can be observed in the higher magnification electron micrographs (right panels). The amyloid load similarly increased with age in both
genotypes, but highly ordered, condensed amyloids were present in AD;Igf1r+/ cortices (arrows) but not in the cortices of their AD counterparts. White scale
bars represent 1 mm, black bars 200 nm.
(B) Unbiased automated image processing indicates that median intensities of regions of interest (ROIs) around the gold particles labeling Ab plaques of
AD;Igf1r+/ mice (black) are significantly (p < 0.04) higher than the plaque intensities of age-matched AD animals (red), confirming the higher compaction state
of Ab plaques of AD;Igf1r+/ (135 images [34,087 ROIs] of AD and 101 images [26,066 ROIs] of AD;Igf1r+/ were collected and analyzed).
(C) Using an in vitro kinetic aggreagtion assay to assess fibril load, 12- to 13-month-old AD;Igf1r+/ mouse brain homogenates (blue) accelerated Thioflavin-T
(ThT) monitored in vitro kinetic aggregation significantly (p = 0.035) faster than homogenates of age-matched AD brains (brown), indicating more Ab seeding
competent assemblies in AD;Igf1r+/ mouse brains. Inset: Statistical analysis of results obtained in (C). Error bars represent mean ± SEM.Ab. Thus, we tested whether more soluble Ab is present in
AD compared to AD;Igf1r+/ brain homogenates. We spun brain
homogenates of sevenAD and nineAD;Igf1r+/ 12- to 13-month-old mice to sediment highly aggregated Ab (10,000 g for 10 min,
4C) and quantified the lower molecular weight (MW) Ab1-40
and Ab1-42 levels in the soluble fractions using enzyme-linkedCell 139, 1157–1169, December 11, 2009 ª2009 Elsevier Inc. 1163
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Figure 6. AD Brains Contain More Soluble Ab Oligomers Than Do Brains of AD;Igf1r+/ Animals
(A and B) ELISA assay detected significantly higher amounts of soluble Ab1-40 (A) (p < 0.001) and Ab1-42 (B) (p < 0.005) in brain homogenates of 12- to
13-month-old AD mice compared with brains of age-matched AD;Igf1r+/ animals.
(C and D) Western blot analysis reveals no detectable difference in the amount of SDS-sensitive Abmonomers and small oligomeric assemblies between AD and
AD;Igf1r+/ brain homogenates. Asterisk (*) indicates significant difference from WT or Igfr1+/ mice.
(E) Native SEC indicated that Ab dimers were mainly associated with large structures in brains of 16- to 17-month-old AD;Igf1r+/ mice (panel iii) while more
soluble in brains of age-matched AD animals (panel ii, arrowhead) (panels represent 6 AD and 6 AD;Igf1r+/ animals that were analyzed). Loading of total samples
onto the gel and subsequent WB analysis using 6E10, confirmed equal protein loading onto the column (panel i).
Error bars represent mean ± SEM (A, B, and D).immunosorbent (ELISA) assays. Ab1-40 (Figure 6A) and Ab1-42
(Figure 6B) levels were significantly (p < 0.001 and p < 0.005,
respectively) lower in the soluble brain supernatant fractions of1164 Cell 139, 1157–1169, December 11, 2009 ª2009 Elsevier Inc.AD;Igf1r+/ mice compared to age-matched (12-13 month) AD
animals. No such differences could be detected in the amounts
of soluble Ab1-40 among young mice (Figure S7A, p = 0.126).
Next, we tested whether SDS-soluble Ab oligomeric content
and total quantities were affected by reduced IGF-1 signaling.
Four AD and 4 AD;Igf1r+/ mouse brains of 12- to 13-month-
old mice were subjected to an Ab oligomer preparation protocol
(Bar-On et al., 2006) followed by SDS-PAGE and western blot
(WB) analysis. Surprisingly, the SDS-soluble Ab oligomer
content, and total quantities and amounts of APP were indistin-
guishable in the total brain homogenates (Figures 6C and 6D) of
AD and of AD;Igf1r+/ mice (no oligomers could be detected in
cytosolic fractions; Figure S7B). The difference between the olig-
omer analysis results and the marked difference in the pool of
nonaggregated Ab species among AD;Igf1r+/ and AD animals
observed by the ELISA assays (Figures 6A and 6B) suggests
that the oligomeric Ab assemblies are SDS sensitive. To test
this, we employed size-exclusion chromatography (SEC) to
analyze the native composition of Ab assemblies in the brains
of AD and AD;Igf1r+/ mice. Brains of AD;Igf1r+/ and AD mice
were homogenized and prepared as done for the ELISA assays
to preserve macromolecular structural integrity. Equal amounts
of cleared homogenates (Figure 6E, panel i) were loaded onto
a size-exclusion column, and 20 fractions were collected, lyoph-
ilized, resuspended, and loaded onto SDS gels. Ab assemblies
were visualized using WB and Ab antibody (6E10). Notably,
higher MW assemblies were observed in the AD;Igf1r+/ (see
red reference line) reflecting that they were larger to begin with
and/or that they were more SDS resistant (Figure 6E, panel iii,
fraction 3) (for size exclusion standard see Figure S7, C and D).
The apparent dimer band resulting from SDS mediated denatur-
ation of much larger aggregates is not observable in the
AD;Igf1r+/ SEC fractions (Figure 6E, panel iii), but is observable
in the AD mouse fractions, (Figure 6E, panel ii, fractions 5–7,
open arrowhead).This proposes that in the AD;Igf1r+/ brains,
Ab fibrils are denser, more SDS resistant and more efficiently
prevent the release of potentially toxic oligomeric species. Since
toxicity has been previously associated with the capacity of high-
MW assemblies to fragment (Shankar et al., 2008), prior correla-
tions between the appearance of small SDS-stabilized Ab
species and neurotoxicity may reflect this. The data obtained
from the microscopic analyses, ELISA and in vitro assays
suggest that the conversion of oligomers into denser, higher
MW, more SDS-resistant aggregates is part of the process that
protects against proteotoxicity in the AD;Igf1r+/ animals.
DISCUSSION
By comparing behavioral and pathological aspects of Alz-
heimer’s-like disease in the AD and AD;Igf1r+/ mice, we found
that reduced IGF-1 signaling notably protects mice from proteo-
toxicity associated with the expression of the AD-linked human
peptide, Ab. Light and electron microscopy, as well as in vitro
kinetic aggregation, ELISA, and SEC assays, all indicate that
reduced IGF-1 signaling induces the assembly of Ab into densely
packed, larger fibrillar structures late in life. The observation that
the protected AD;Igf1r+/ mice form SDS stable Ab assemblies,
making it more difficult to generate presumably toxic Ab dimers
(Shankar et al., 2008), suggests that an active mechanism con-
verts oligomers into densely packed aggregates of lower toxicity
that protect the AD;Igf1r+/ mice from proteotoxicity. Thishypothesis is consistent with results obtained in the Ab worm
model, where reduced insulin/IGF signaling protected worms
from Ab-associated toxicity while increasing the formation of
high-MW Ab aggregates (Cohen et al., 2006).
How can increased Ab aggregation protect against proteotox-
icity? Highly aggregated Ab is thought to bear lower toxicity in
comparison to oligomers (Haass and Selkoe, 2007). Accordingly,
enhanced fibrillization can reduce Ab toxicity in an AD-murine
model (Cheng et al., 2007). Furthermore, results from long-
term potentiation assays show that highly aggregated Ab bears
lower toxicity than small oligomers (Shankar et al., 2008). Intrigu-
ingly, the release of small oligomers, most notably dimers, from
large Ab assemblies (fibrils) by chemical extraction increases
toxicity. In support of the hypothesis that accelerated aggrega-
tion can be protective is provided by the discoveries that the
cellular chaperones HSP104 (Shorter and Lindquist, 2004) and
TRiC (Behrends et al., 2006), both known to disrupt toxic protein
aggregates can also mediate protection by accelerating aggre-
gation when the concentration of the aggregating protein ex-
ceeded a threshold level. These studies raise the prospect that
the creation of densely packed, large Ab assemblies protects
AD;Igf1r+/ mice from proteotoxicity by trapping and storing
highly toxic small aggregate structures. If active aggregation
protects from Ab toxicity, such protective mechanism might be
expected to be negatively regulated by the IGF signaling
pathway. In the worm, this activity is mediated, at least in part,
by the FOXO transcription factor DAF-16 (Cohen et al., 2006),
which is negatively regulated by the IIS receptor DAF-2. The
FOXO gene family is highly conserved in mammals, is expressed
in neurons, and is required for neuronal survival under stress
(Lehtinen et al., 2006), suggesting that FOXO transcription
factors are also mediators of the reduced IGF signaling protec-
tive effect in mammals.
It is likely that reduced IGF signaling ameliorates Ab proteotox-
icity by mechanisms in addition to Ab dense fibril formation. The
observation that Igf1r+/ mice exhibit increased resistance to
oxidative stress (Holzenberger et al., 2003) raises the possibility
that reduced IGF-1 signaling enhances the neuronal counter
proteotoxic capabilities by enhancing the levels of enzymes
that protect against oxidative stress proposed to be involved
in AD-associated brain damage (Fukui et al., 2007). This is
supported by the observation that the production of reactive
oxygen species is reduced in brains of Igf1r+/ mice compared
with their WT counterparts following MPTP treatment known to
induce a Parkinson’s disease-like phenotype (Nadjar et al.,
2008). Moreover, overexpression of mitochondrial-targeted
catalase promotes longevity of mice (Schriner et al., 2005). An
alternative model suggests that increased neuronal resilience
associated with reduced IGF signaling is promoted by enhanced
DNA repair capabilities. It is reasonable to speculate that the
histone deacetylase SIRT1, an aging regulator (Ghosh, 2008)
that plays roles in the maintenance of genomic stability (Ober-
doerffer et al., 2008) and regulates HSF1 (Westerheide et al.,
2009), may also be a mediator of the reduced IGF signaling
protective effect in the AD;Igf1r+/ mice. The complexity and
variety of effects mediated by FOXO (Partridge and Bruning,
2008) propose that reduced IGF signaling orchestrates an array
of counter proteotoxic activities including Ab hyperaggregation,Cell 139, 1157–1169, December 11, 2009 ª2009 Elsevier Inc. 1165
counter oxidation activities, and presumably other yet to be
defined mechanisms (Figure 7). Further research is required to
elucidate whether mammalian FOXO family members play roles
in the protective mechanism toward AD.
The Ab hyperaggregation observed in protected AD;Igf1r+/
mouse brains suggested that Ab plaques would be visible in
the cortex of these animals at younger ages compared to their
unprotected AD counterparts, however, this was not evident in
our analysis. This is likely due to other mechanisms of protein
homeostasis being effective early in life, such as the disaggre-
gase and degradation activity regulated by HSF-1, as observed
in the worm (Cohen et al., 2006). In this view, the protective
disaggregation/degradation and hyperaggregation mecha-
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Figure 7. IGF-1 Signaling Can Play Several Roles in Mitigating the
Toxicity of Ab
The digestion of APP creates Ab monomers that spontaneously aggregate to
form toxic oligomers in vivo. At least two biological mechanisms can detoxify
Ab oligomers: (1) conversion of toxic oligomers into monomers (disaggrega-
tion), and (2) conversion of toxic oligomers into less toxic, larger structures
(active aggregation). Within scenario 1, IGF-1 signaling normally functions to
reduce protein disaggregases. Therefore, reduction of IGF-1 signaling would
result in less oligomers and more monomeric forms of Ab due to the activation
of protein disaggregases. Our results are inconsistent with this scenario
because we find less oligomers, but equal amounts of monomeric Ab. Alterna-
tively, in scenario 2, IGF-1 signaling could normally function to reduce protec-
tive protein aggregases that convert toxic species into larger, less toxic forms.
Thus, reduced IGF-1 signaling elevates aggregase activity that in turn reduces
the load of toxic oligomers and increases the compaction of less toxic fibrils. In
support of scenario 2, we observed less soluble oligomers and highly compact
amyloid plaques in AD;Igf1r+/ animals. Alternatively, (3) IGF-1 signaling could
promote proteotoxicity and neuroinflammation in response to toxic Ab assem-
blies. Our results are also consistent with this proposed mechanism as we
observed much less neuroinflammation in the brains of protected AD;Igf1r+/
animals. Yet this lower inflammation rate could be directly related to the reduc-
tion of Ab oligomers in these animals by increased aggregases. In scenario 4,
reduction of toxic secondary factors, such as reactive oxygen species (ROS),
might synergize with the production of toxic Ab assemblies to promote
neuronal loss. Consistent with this mechanism, Igf1r+/ mice are much more
resistant to oxidative damage than wild-type mice. Taken together, IGF-1
signaling could impinge at multiple steps on the path to neuronal loss and
neurodegeneration in response to Ab production and none of the interventions
are mutually exclusive. Our data are most consistent with a model in which
reduced IGF-1 signaling reduces the load of toxic Ab structures, presumably
dimers, which results in higher compaction of plaques, reduced neuroinflam-
mation, and reduced neuronal loss.1166 Cell 139, 1157–1169, December 11, 2009 ª2009 Elsevier Inc.nisms may be temporally distinct. Active hyperaggregation
may only be invoked once the primary disaggregation ma-
chinery can no longer effectively clear toxic Ab species as
a consequence of aging or an extrinsic stress. It will be inter-
esting to evaluate whether one or more of the four HSF genes
in the mouse are involved in protecting the brain from Ab
toxicity throughout life, and whether FOXO activity becomes
prominent later in life.
There is an apparent contradiction between the data pre-
sented herein and earlier reports that IGF infusion protects rats
(Carro et al., 2002) and mice (Carro et al., 2006) from Ab proteo-
toxicity and that IGF-1R blockade induced neurological disease
in rats (Carro et al., 2006). The presence of feedback-signaling
events that respond to the sudden increase in IGF concentration
by tuning down the responsiveness of the IGF signaling cascade
over time could explain why IGF infusion is protective against
AD-like pathology (Cohen and Dillin, 2008). This explanation is
supported by many observations. For example, long-lived
female human centenarians have high serum IGF-1 levels, but
low IGF-1R activity, leading to reduced IGF signaling (Suh
et al., 2008). Therefore, high IGF-1 levels do not necessarily
correlate with increased downstream activity over a prolonged
time. Additionally, AD patients have lower than normal serum
insulin concentrations, but higher than normal CSF insulin levels
(Craft et al., 1998). These studies raise the prospect that insulin
and IGF signaling are regulated in a tissue-specific manner,
and suggest that peripheral IGF infusion may lead to reduced
IGF signaling in the brain (Cohen and Dillin, 2008).
The data presented here demonstrate that reduced IGF-1R
signaling results in a profound reduction in the toxicity associ-
ated with Ab expression in the brains of mice. The formation of
larger and denser Ab aggregates that appear to be more SDS
resistant in the AD;Igf1r+/ mice suggests that this is one core
protective activity regulated at least in part by IGF-1R signaling,
much like the disaggregase activity reported previously (Cohen
et al., 2006). The indication that reduced IIS is protective in
nematodes and mammals stresses that manipulation of the
highly conserved IGF signaling pathway, and its downstream
components, is promising for the development of novel neurode-
generation and proteotoxicity therapies.
EXPERIMENTAL PROCEDURES
Mouse Strains and Genotyping
AD-model male mouse expressing a mutant chimeric mouse/human APPswe
and a mutant human presenilin 1 (Delta E9) both driven by the prion protein
promoter was purchased from Jackson laboratory (strain B6C3-Tg [APPswe
PSEN1 dE9] 85Dbo/J, stock number 004462).
Long-Lived, Compromised IIS Mice
Males harboring only one Igf1r copy (S129 background [Holzenberger et al.,
2003]) were obtained from Dr. Jeffery Friedman (TSRI, La Jolla, CA). Males
of both strains were crossed for three generations with ‘‘wild-type’’ 129
females (Jackson laboratories, strain 129Xi/SvJ, stock number 000691), to
set up two separate colonies. Mice of each colony were backcrossed for addi-
tional two generations. Next, Igf1r+/males were crossed with AD females for
three generations to generate the experimental mice.
DNA was purified from biopsies of mouse tails and subjected to PCR.
APPswe and PS1DE9 were amplified as directed by the Jackson Laboratories.
Igf1r was amplified using the following primers: forward: GTATAGTCCTA
GAGGCCC; reverse: GTTCTGGCAGAAAACATGG.
Western Blot Analysis
Brains were dissected, homogenized, and divided by ultracentrifugation
(100,000 g, 1 hr, 4C) into cytosolic and membrane (particulate) fractions.
For WB analysis, 15 mg per lane of cytosolic and particulate fractions, assayed
by the Lowry method, were loaded into 10% SDS-PAGE gels and blotted onto
nitrocellulose paper. Blots were incubated O/N with antibodies against APP/
Ab (6E10), Ab (82E1), and C terminus APP (CT-15, courtesy of Dr. Ed Koo).
Next, membranes were incubated with secondary antibodies tagged with
horseradish peroxidase (1:5000, Santa Cruz Biotechnology, Inc., Santa
Cruz, CA), visualized by enhanced chemiluminescence and analyzed with
a Versadoc XL imaging apparatus (Bio-Rad, Hercules, CA). Actin served as
a loading control.
Rota Rod
Locomotion was tested using Rota Rod system (EconoMex, Columbus Instru-
ments, Columbus, OH). Four mice were place at a time on the rotating beam
set to accelerate at 0.2 rpm/s.
Time from start until each mouse fell off was recorded. Each mouse was
trained 1 day for five times prior to the experiment. Each mouse was tested
five times a day, for 4 sequential days (total of 20 measurements/mouse/
age). At least 12 animals (males and females) per genotype were used in
each time point (Supplemental Statistical Data).
Morris Water Maze
The Morris water maze was conducted as described previously (Jensen et al.,
2005). Briefly, 11- to 15-month-old mice of the four genotypes were placed one
animal per cage and numbered randomly to avoid genotype identification
during the experiment. A plastic tank 120 cm in diameter was filled with
room temperature (RT) water (23C), which was made opaque with white
nontoxic paint. A transparent platform (8 cm 3 12 cm) was located in the
center of one of the four virtually divided quadrants and was submerged
0.5 cm below the water surface to be invisible. Distal cues were provided in
all experiments as spatial references. Mice were let swim until platform was
found or for a maximum of 60 s. Mice were allowed to rest on the platform
for 15 s between trials. In all experimental settings we utilized a video tracking
system (Ethovision; Noldus Information Technology, Leesburg, VA) to record
and analyze the swimming path, swim velocity, time taken to reach the
platform (latency), and time spent in each quadrant. The experiments were
performed at the following order: cued platform (4 sequential days), hidden
platform (4 sequential days), probe trial (1 day). The number of animals used
was 13 (WT), 12 (Igf1r+/), 8 (AD), and 15 (AD;Igf1r+/).
Cued Platform
For the cued version of water maze testing, the platform was located 0.5 cm
below the opaque water level but made clearly visible to the mouse by locating
a 15 cm high stick carrying a dotted flag (3 cm 3 4 cm) on the platform. The
platform location was fixed throughout the experiment. The mice were
released from four different locations around the water tank.
Hidden Platform
The platform was located at the same location used for the cued platform
experiment, 0.5 cm below the opaque water level but without the dotted
flag, to be invisible. The mice were released from four different locations
around the tank. Time of latency, swim velocity, path length, and time spent
at each quadrant were recorded.
Probe Trial
The platform was removed and the mice were allowed to swim for 40 s. The
time spent in each quadrant and in the previous platform location, number
of crossing the area where the platform was previously located, swim velocity,
and path length were recorded.
Size-Exclusion Chromatography
A Superdex 75 10/300 GL column (Cat # 17-5174-01 GE Healthcare, Uppsala
Sweden) attached to an AKTA FPLC system was used to separate Ab oligo-
mers from mouse brains. Column was calibrated using low MW calibration
kit (GE Healthcare cat # 28-4038-41). Then 250 ml 10% (w/v) mouse brainhomogenate (in PBS) was injected into the column and eluted with 50 mM
ammonium acetate (pH 8.5) at flow rate of 0.5 ml/min. Twenty 1 ml fractions
were collected, lyophilized, resuspended in 120 ml PBS and 40 ml LDS sample
buffer, boiled for 10 min, and separated on 4%–12% Bis-Tris gels as described
above.
Morphological and Postembedding Immunoelectron Microscopy
WT, Igf1r+/, AD, and AD;Igf1r+/ mice were sacrificed at the indicated ages.
A piece of cortex from each mouse brain was fixed for 24 hr in cold 2% para-
formaldehyde and 0.25% glutaraldehyde in PBS followed by washing in PBS
and postfixed in 1% osmium tetroxide in PBS. The samples were washed in
PBS and dehydrated in graded ethanol solutions followed by propylene oxide
and embedded in Epon/Araldite mixture (Cat # 13940, Electron Microscopy
Sciences, Hatfield, PA). The polymerized resin was sectioned (70 nm) using
a diamond knife (Diatome, Hatfield, PA) and mounted on uncoated 400
mesh nickel grids (Cat# G400-Ni, Electron Microscopy Sciences) for immuno-
labeling. Antigen retrieval was performed using sodium m-periodate-saturated
aqueous solution for 10 min followed by TBS (50 mmol/l Tris–HCl, 150 mmol/l
NaCl [pH 7.4]) wash. Sections were background blocked in 3% bovine serum
albumin (BSA) in TBS for 30 min followed by an overnight incubation in primary
Ab1-42 affinity purified polyclonal rabbit antibody, which recognizes the C
terminus of the peptide (Cat # AB5078P Chemicon-Millipore, Temecula, CA)
1:50 in 1% BSA in TBS at RT. Sections were washed 3 times in TBS and
blocked in 3% BSA in TBS for 30 min followed by 2 hr incubation in protein
A conjugated to 10nm gold particles (Cat # EM PAG10 BB International,
Cardiff, UK) diluted 1:100 in 1% BSA in TBS at RT, rinsed three times in
TBS, three times in H2O, and air dried. Higher contrast was achieved with
2% uranyl acetate in 50% ethanol for 10 min and in Reynold’s lead citrate
solution (120 mmol/l sodium citrate, 25 mmol/l lead citrate [pH 12]) for
1.5 min. The specimens were studied in a Jeol 100CX electron microscope
(Jeol, Akishima, Tokyo, Japan) at 100 kV. Electron micrographs were taken
with a Mega View III CCD camera (Soft Imaging System GmbH, Muenster,
Germany) and Analysis Pro v 3.2 digital micrograph software (Soft Imaging
System GmbH). For detailed description and software for EM particle analysis,
please see Supplemental Data and http://sites.dillinlab.googlepages.com.
In Vitro Kinetic Ab Aggregation Assay
Ab1-40 peptide (10 mM in phosphate buffer: 300 mM NaCl, 50 mM Na-phos-
phate [pH 7.4]) was labeled with ThT (20 mM). Mouse brain homogenate was
sonicated for 40 min (FS60, Fisher Scientific, Pittsburg, PA), treated with
proteinase K (2h, 0.2 mg/ml), and supplemented with complete EDTA-free
protease inhibitor cocktail (cat#1836170 Roche, Basel Switzerland). Three
aliquots (100 ml each, total protein concentration of 10 mg/ml) were transferred
into a 96-well microplate (Costar black, clear bottom) for each reaction. The
plate was loaded into a Gemini SpectraMax EM fluorescence plate reader
(Molecular Devices, Sunnyvale, CA), incubated at 37C, and fluorescence
(excitation at 440 nm, emission at 485 nm) was measured from the bottom
at 10 min intervals, with 5 s of shaking before each reading. Half-maximal
fluorescence time points (t50) were defined as the time point at which ThT
fluorescence reached the middle between pre- and postaggregation base-
lines. Fluorescence traces and t50 values represent averages of at least three
independent experiments.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures and
seven figures and can be found with this article online at http://www.cell.
com/supplemental/S0092-8674(09)01426-3.
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